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The  current  emergence  of antibiotic-resistant  bacteria  causes  major  problems  in  hospitals  worldwide.  To
survive  within  the  host,  bacterial  pathogens  exploit  several  escape  mechanisms  to  prevent  detection  and
killing  by  the  immune  system.  As  a major  player  in  immune  defense,  the complement  system  recognizes
and  destroys  bacteria  via  different  effector  mechanisms.  The  complement  system  can  label  bacteria  for
phagocytosis  or  directly  kill  Gram-negative  bacteria  via  insertion  of  a pore-forming  complex  in  the  bacte-
rial  membrane.  The  multi-drug  resistant  pathogen  Klebsiella  pneumoniae  exploits  several  mechanisms  to
resist  complement.  In this  review,  we present  an  overview  of strategies  used  by K.  pneumoniae  to  prevent
recognition  and  killing  by  the  complement  system.  Understanding  these  complement  evasion  strategies
is  crucial  for  the  development  of  innovative  strategies  to combat  K.  pneumoniae.
©  2016  The  Authors.  Published  by  Elsevier  GmbH.  This  is  an open  access  article  under  the  CC  BY
license (http://creativecommons.org/licenses/by/4.0/).
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1. Klebsiella pneumoniae
K. pneumoniae is a non-motile Gram-negative aerobic rod that
causes a wide variety of hospital-acquired infections. This bac-
terium colonizes a wide range of hosts ranging from plants to
mammals, but can also be found in the soil and surface water
(Podschun et al., 2001). Normally, individuals carry K. pneumoniae
asymptomatically on the skin, in the nose and throat (Bagley, 1985).
In immunocompromised individuals, neonates and the elderly, K.
pneumoniae can cause severe hospital-acquired infections such as
pneumonia and urinary tract infections. In addition, certain hyper-
∗ Corresponding author.
E-mail address: b.w.bardoel-2@umcutrecht.nl (B.W. Bardoel).
virulent K. pneumoniae strains can cause community-acquired
infections  (Brisse et al., 2009). Acquisition of antibiotic resistance
genes and intrinsic resistance to several classes of antibiotics
limits treatment options for infections caused by K. pneumoniae.
Currently, K. pneumoniae strains producing Extended Spectrum
Beta-Lactamases (ESBLs) and carbapenemases have spread globally
(Hawkey and Jones, 2009). These enzymes inactivate -lactams, a
class of antibiotics that forms the basis of effective treatment for
patients suffering from infections with K. pneumoniae. As a result
the antimicrobial peptide (AMP) colistin (also known as polymyxin
E) has been reintroduced to treat infection with multidrug resis-
tant K. pneumoniae. However, the acquisition of colistin resistance
by chromosomal mutations and the plasmid-associated gene mcr-1
have recently been reported (Liu et al., 2015; Olaitan et al., 2014),
acutely threatening the effectiveness of colistin as an antibiotic of
http://dx.doi.org/10.1016/j.imbio.2016.06.014
0171-2985/© 2016 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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last resort for multi-drug resistant Klebsiella infections. Some clin-
ical K. pneumoniae isolates are resistant to all available antibiotics
(Elemam et al., 2009). The rise of these multi-drug resistant iso-
lates warrants the development of novel classes of antibiotics or
alternative treatment strategies.
Traditionally, classiﬁcation of K. pneumoniae isolates was per-
formed by capsular serotyping (K-typing) using speciﬁc antisera
(Podschun and Ullmann, 1998). There are 79 capsular serotypes,
but the majority of infections in humans are caused by a limited
number of serotypes (Brisse et al., 2013). K. pneumoniae strains
belonging to the K1 and K2 serotypes are known as hypervirulent,
causing community-acquired infections in the form of pyogenic
liver abscesses (Fung et al., 2002; Struve et al., 2015). Next to cap-
sular typing, K. pneumoniae isolates are also typed on the basis
of the polysaccharide O-antigen (O-typing). The O-antigen pro-
trudes from the outer membrane and is the outermost domain
of lipopolysaccharide (LPS) that form an essential component of
the cell wall of Gram-negative bacteria. The O1 serotype is the
most prevalent serotype among clinical isolates (Hansen et al.,
1999). Recently, differentiation by genome sequencing has been
introduced (Bialek-Davenet et al., 2014). Detailed genomic analysis
revealed that strains belonging to clonal complex 258 (CC258) are
highly enriched in K. pneumoniae isolates originating from hospital-
acquired infections (Holt et al., 2015).
To survive within the human host, bacteria have developed sev-
eral lines of counter-attack and evasion strategies. Like many other
opportunistic pathogens, K. pneumoniae has various virulence fac-
tors that help the bacterium survive within the host (Podschun and
Ullmann, 1998). However, compared to other clinically important
bacteria, the repertoire of genes involved in colonization and infec-
tion is incompletely deﬁned. As one of the most obvious protective
structures the capsule has been well-studied in K. pneumoniae
(March et al., 2013). The capsule protects against phagocytosis,
antimicrobial peptides and complement-mediated lysis. Hyper-
virulent K. pneumoniae strains, belonging to clonal complex 23
aquired a large virulence plasmid encoding different virulence fac-
tors, including siderophores (Struve et al., 2015). The acquisition
of iron via siderophores is crucial for growth and virulence within
the host. Deletion of the gene encoding for the siderophore aer-
obactin reduced growth in serum and virulence in a lung infection
model (Russo et al., 2015). In order to colonize the host, K. pneu-
moniae uses type I pili for adherence to different surfaces like the
mucosa (Murphy et al., 2013; Rosen et al., 2015). Deletions of genes
involved in type I pili synthesis and regulation reduce virulence in
mice. After colonization, K. pneumoniae can survive, for instance
in alveolar macrophages, to evade killing in the phagosome (Cano
et al., 2015).
Because of its emergence as a multi-drug resistant pathogen,
it is crucial to better understand the mechanisms by which K.
pneumoniae can survive within the human host. Apart from vir-
ulence mechanisms to adhere to tissues (pili) or acquire iron
(siderophores), this bacterium has also evolved ways to circumvent
clearance by the immune system, which is an important requi-
site for pathogenic bacteria. Although our collective insights into
complement evasion mechanisms of K. pneumoniae have increased,
these have not yet been subject for review. Here, we aim to pro-
vide a comprehensive overview of the interactions of this important
human pathogen with the complement system.
2. The complement system
The  complement system belongs to the ﬁrst line of immune
defense and consists of a network of plasma proteins that trig-
ger a proteolytic cascade upon recognition of several microbial
patterns (Ricklin et al., 2010; Walport, 2001). Activation leads to
the deposition of complement proteins on the bacterial surface,
thereby labeling bacteria for phagocytic uptake and subsequent
killing. Three distinct pathways initiate complement activation. In
the classical complement pathway, the complement protein C1q
recognizes antigen-antibody complexes and triggers the gener-
ation of C3 convertase enzymes, which cleave the complement
protein C3 into C3b, which covalently attaches to bacterial surfaces
(Fig. 1a). Similarly, in the lectin pathway Mannose-Binding Lectin
(MBL) or ﬁcolins that recognize sugar motifs or cell wall polymers
that are speciﬁcally present on microbial surfaces trigger the for-
mation of a C3 convertase. The alternative pathway is generally
seen as an ampliﬁcation loop to enhance C3b deposition follow-
ing initiation of complement activity via the classical and lectin
pathway.
Complement receptors expressed on phagocytic cells recognize
C3b on bacteria, triggering phagocytosis of the opsonized bacte-
ria. After phagocytosis, bacteria end up in the phagosome where
they are attacked by several antimicrobial proteins and reactive
oxygen species. The deposition of C3b also triggers formation of
C5 convertases that cleave C5 into C5b, which initiates the forma-
tion of the membrane attack complex (MAC). This multi-protein
complex consists of the proteins C5b, C6, C7, C8, and multiple
copies of C9 (C5b-9) and can speciﬁcally kill Gram-negative, but
not Gram-positive bacteria, via pore formation in the outer mem-
brane (Berends et al., 2014). The cell wall of Gram-negative bacteria
consists of an outer membrane, a periplasmic space with a thin
peptidoglycan layer, both of which lie outside the inner membrane
(Fig. 1b). The MAC  targets the outer membrane, however the exact
mechanism by which the MAC  causes cell lysis in Gram-negative
bacteria remains unclear (Berends et al., 2014). In Gram-positive
bacteria, the thick peptidoglycan layer is thought to prevent lysis
by the MAC. Next to stimulating phagocytosis and direct killing
through MAC-mediated bacterial cell lysis, the chemoattractant
C5a is also released during the proteolytic cascade of the com-
plement system and attracts immune cells to the site of infection.
Furthermore, the adaptive immune response can be enhanced as
a result of complement activation. This can be achieved in var-
ious ways, for instance by inducing cross-talk between antigen
presenting cells or via detection of complement cleavage products
by complement receptors expressed on B and T cells (Carroll and
Isenman, 2012; Strainic et al., 2008; Wagner et al., 2006).
3.  Complement activation by K. pneumoniae
Before we  discuss complement evasion, we will ﬁrst describe
how the complement cascade is activated on K. pneumoniae. First,
outer membrane proteins and lipopolysaccharide of K. pneumoniae
are known to activate the classical pathway (Alberti et al., 1996a).
Binding of C1q activates C1s resulting in formation of a C3 con-
vertase that cleaves C3 into C3b, exposing a previously hidden
thioester that covalently links C3b to surfaces in close proximity
to the activation site. As surface exposed molecules, lipopolysac-
charide and outer membrane proteins (OMPs) in K. pneumoniae
serve as important targets for C3b deposition (Alberti et al., 1996a;
Galdiero et al., 1984; Mishra et al., 2015). OMPs have various roles
in the interaction with the immune system of the host, such as
resistance against antimicrobial peptides and activation of den-
dritic cells (Jeannin et al., 2000; Llobet et al., 2009). The abundantly
expressed outer membrane protein K36 (OmpK36) of K. pneu-
moniae binds C1q in an antibody-independent way and activates
the classical pathway (Alberti et al., 1993, 1996b). The globular
domains of the heterotrimer C1q directly interact with OmpK36 of
K. pneumoniae (Alberti et al., 1996b; Kojouharova et al., 2003). This
direct interaction also leads to complement activation, resulting in
the deposition of C3b and C5b-9. Furthermore, puriﬁed LPS from
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Fig. 1. Complement activation and the Gram-negative cell structure.
(A)  Schematic overview of the complement system. Activation occurs via recognition of antibodies by C1q in the classical pathway or via recognition of sugar motifs via MBL
or  ﬁcolins. This leads to activation and cleavage of several complement proteins leading to deposition of C3 convertases that cleave C3 into C3b. The alternative pathway
ampliﬁes C3 cleavage by generating additional C3 convertases leading to massive C3b labeling of the bacterial surface. The deposition of C3b triggers phagocytosis and
formation of C5 convertases that cleave C5 into the chemoattractant C5a and C5b, which initiates formation of the membrane attack complex. (B) Gram-negative bacteria
have a thin peptidoglycan layer located in the periplasmic space between the outer and inner membrane. The capsule consists of a polysachharide layer that protects the
bacterium from the outside environment.
K. pneumoniae can activate the alternative complement pathway
(Alberti et al., 1993). The structure of LPS differs between K. pneu-
moniae strains and inﬂuences the potency to activate complement,
as will be discussed later.
Capsular  polysaccharide patterns of some K. pneumoniae strains
can induce activation of the lectin complement pathway via the
interaction with MBL  (Sahly et al., 2009). This occurs by recognition
of capsular polysaccharides containing mannobiose or rhamno-
biose. Poorly encapsulated strains show a relatively high level
C3b on their surface and are phagocytosed by lung epithelial cells
(Astorza et al., 2004; Cortés et al., 2002a). Loss of the capsular
polysaccharides inhibits virulence, which correlates with loss of
serum resistance as will be discussed in more detail in the next
sections.
4. Complement evasion strategies by K. pneumoniae
4.1. Protection by the capsule
The  capsule of K. pneumoniae is a dense, ∼160 nm thick layer
of polysaccharide ﬁbers that effectively protects the bacterium
from hostile environments (Amako et al., 1988). Deletion of the
genes  necessary for capsule formation in clinical strains drasti-
cally impairs virulence of K. pneumoniae, resulting in a virtually
non-pathogenic bacterium (Lawlor et al., 2005). Capsular polysac-
charides are high molecular weight structures with linear or
branched repeating units of two  to seven monosaccharides (Zamze
et al., 2002). Capsular switching of K. pneumoniae strains belong-
ing to the hospital-enriched CC258 indicates that the composition
of the capsular polysaccharide can quickly change and is impor-
tant for virulence (Wyres et al., 2015). Several studies showed that
the capsule of K. pneumoniae provides an efﬁcient barrier to pre-
vent bacterial killing via the MAC  (Fig. 2a) (Clements et al., 2007;
Fang et al., 2004; Lin et al., 2012). In clinical isolates the capsule
protected against serum killing and C3b deposition via the three
different complement activation pathways (Alvarez et al., 2000;
Merino et al., 1992). The deposition of C3b is dependent on the
thickness of the capsule of K. pneumoniae, probably because the
capsule masks antibody epitopes on the bacterial surface, poten-
tially blocking the activation of complement entirely (Astorza et al.,
2004; Domenico et al., 1999).
The capsular polysaccharide motifs vary between different K.
pneumoniae strains and are detected to different degrees by the
innate immune system. Certain K. pneumoniae strains can mod-
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Fig. 2. Complement evasion by K. pneumoniae.
(A) Role of the capsule in complement evasion. K. pneumoniae modiﬁes sugar struc-
tures that fail to activate the lectin pathway, thereby preventing C3b and MAC
deposition.  In addition, the thick polysaccharide layer creates a physical barrier
around the bacterium that prevents proper insertion of the MAC  and subsequent
bacterial  lysis. RfaH and HtrA increase serum resistance and have been associated
with  a change in capsule formation. (B) Evasion of complement activation by LPS.
Elongation of the O-antigen blocks recognition of surface epitopes by antibodies or
directly via C1q and activates complement far from the outer membrane, which pre-
vents proper insertion of the MAC  into the outer membrane. In addition, O-antigen
side  chains decrease deposition of C3b and the MAC. Modiﬁed glycan structures at
the terminal end of the K. pneumoniae O-antigen diminish complement activation.
ify their capsular composition to prevent recognition by the lectin
pathway, as was reported in strains of the K2 serotypes that
have an altered glycan composition (Sahly et al., 2009). These
strains lack mannobiose or rhamnobiose, which are recognized
via the lectin pathway. Sialylation of the terminal end of capsular
polysaccharide slightly inhibits complement-mediated phagocyto-
sis of hypermucoidic K. pneumoniae strains (Lee et al., 2014). The
enzymatic removal of sialic acid restored complement-mediated
phagocytosis. In conclusion, the capsule of K. pneumoniae forms an
important shield that limits complement activation, in addition to
other important functions such as protection against antimicrobial
peptides.
4.2. Lipopolysaccharide
The capsule forms the major physical barrier for the membrane
attack complex, but the outer membrane of K. pneumoniae forms
the main target for the MAC. As a major component of the Gram-
negative cell wall, lipopolysaccharide (LPS) plays an important role
in outer membrane stability and protection against the outside
environment. For Gram-negative bacteria, LPS is crucial for ﬁtness,
but modiﬁcations in LPS are common and necessary to adapt to
different environments (Needham and Trent, 2013). LPS consists of
a glycan polymer or O-antigen that is connected with a polysac-
charide core to lipid A, which is hydrophobic and anchors LPS into
the bacterial outer membrane (Fig. 1b). Cationic antimicrobial pep-
tides can disrupt the outer membrane by displacing cations such
as Mg2+ which normally stabilize the outer membrane through
electrostatic interactions between lipid A moieties. Moreover, the
innate immune system recognizes the lipid A part of LPS via Toll-
like receptor 4 (TLR4), which is expressed on various immune cells
and reacts upon the detection of LPS with cellular activation and
cytokine production (Poltorak et al., 1998). Variations in the struc-
ture of lipid A drastically affect the capacity of lipid A to stimulate
TLR4. Additionally, lipid A modiﬁcations may  possibly inﬂuence the
interaction with the host complement negative regulator factor H,
as previously observed for Neisseria gonorrhoeae (Lewis et al., 2010).
K. pneumoniae has also evolved several mechanisms by which it can
modify its lipid A during colonization and infection, indicating that
lipid A modiﬁcations are essential to ensure survival within the host
(Llobet et al., 2015).
In  several Gram-negative bacteria, other modiﬁcations of LPS
have been shown to lead to changes in serum resistance (Schiller
and Joiner, 1986). Such LPS modiﬁcations include elongation and
changes in polysaccharide composition of the O-antigen side chain.
The O-antigen is highly variable and is recognized by antibodies
since this part of LPS is surface exposed. K. pneumoniae strains with
a long O-antigen produce a high molecular weight (smooth phe-
notype) LPS, whereas strains lacking O-antigen side chains have a
low molecular weight (rough phenotype) LPS. In general, strains
with rough LPS are more susceptible to serum killing, compared to
strains with smooth LPS (Ciurana and Tomas, 1987; McCallum et al.,
1989). Interestingly, isolates with rough LPS activate the classical
pathway, whereas smooth LPS activates the alternative pathway
(Alberti et al., 1993). The long O-antigen in smooth LPS probably
protects either direct C1q binding or binding to antibodies directed
against K. pneumoniae surface molecules. Consequently, elongation
of the O-antigen side chains leads to C3b deposition further away
from the surface (Merino et al., 1992). This prevents proper depo-
sition of the MAC  on the bacterial membrane, resulting in reduced
pore formation and bacterial killing. Analysis of opsonization of
different K. pneumoniae strains revealed slightly lower C3b and no
C5b9 deposition on the bacterial surface of serum resistant strains
(Merino et al., 1992). This illustrates that K. pneumoniae can block
the formation of the MAC  by two  mechanisms, either by steri-
cally hindering the MAC  from reaching the outer membrane or by
inhibiting complement deposition by blocking epitopes of surface
molecules recognized by antibodies or by C1q directly (Fig. 2b).
In other Gram-negative bacteria elongation of the O-antigen pre-
vents killing by the MAC  in a similar way (Grossman et al., 1987;
Kintz et al., 2008; Phan et al., 2013). Adding puriﬁed K. pneumo-
niae LPS to strains that are sensitive to serum effectively inhibited
serum-mediated killing, in contrast to puriﬁed capsular polysac-
charides (Merino et al., 1992). Finally, K. pneumoniae and other
Gram-negative bacteria secrete LPS-containing outer membrane
vesicles that can absorb complement proteins, thereby inhibiting
complement deposition on the bacterial surface (Lee et al., 2012;
Pettit and Judd, 1992).
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An epidemic multi-drug resistant K. pneumoniae clone (CC258)
causes problematic hospital-acquired infections, which are difﬁcult
to treat due to widespread antibiotic resistance (Tzouvelekis et al.,
2013). Isolates belonging to this clone have a modiﬁed capsule and
the majority of the strains in CC258 also have a modiﬁed O-antigen
structure (Szijártó et al., 2015; Wyres et al., 2015). O-antigens con-
sists of galactose repeats (i.e. galactan) that varies depending on
the O-antigen serotype (D-galactan I or II). These galactans have
a different capping of the galactose repeat resulting in a change of
antigenicity. Recently, a modiﬁed D-galactan I structure was identi-
ﬁed in ST258 and named D-galactan IIII (Szijártó et al., 2015). Strains
of ST258 expressing D-galactan III show an improved survival in
human serum compared to isogenic strains expressing D-galactan
I. In contrast, another study showed no effect on serum-mediated
bacterial killing when deleting the gene encoding a galactosyltrans-
ferase responsible for synthesis of the D-galactan I of the O-antigen
(Shankar-Sinha et al., 2004). These ﬁndings suggest that the O-
antigen composition is not directly involved in serum resistance.
However, in the same study the authors also show that the O-
antigen contributes to virulence in a complement C3-dependent
way, suggesting that in vivo other complement effector functions
play a more important role than lysis by the MAC. The use of
different K. pneumoniae strains may  explain variations between
studies regarding the role of the O-antigen in serum resistance.
In summary, the O-antigen plays a major role in modulation of
complement activation in K. pneumoniae.
4.3. Outer membrane proteins
In addition to the modiﬁcation of the capsular polysaccharides
and LPS structures, K. pneumoniae also uses outer membrane pro-
teins to escape detection by the complement system. Deletion of
the genes encoding the outer membrane proteins peptidoglycan-
associated lipoprotein (Pal) and murein lipoprotein (LppA) reduced
serum survival of K. pneumoniae, in contrast to deletion of ompA
(Hsieh et al., 2013). Deletion of lppA decreased the ability of K.
pneumoniae to survive in serum only slightly, whereas serum sus-
ceptibility increased dramatically in the pal deletion mutant. In
addition to increased serum susceptibility, phagocytosis of the pal
and lppA mutants was increased considerably (Hsieh et al., 2013).
The exact role of Pal and LppA in resistance of K. pneumoniae
against phagocytosis, and whether reduced complement activation
is responsible for impaired phagocytosis, remains to be determined.
A similar screening in uropathogenic E. coli also identiﬁed murein
lipoprotein as an important protein for serum survival (Phan et al.,
2013). Both the pal and lppA mutants have an increased outer mem-
brane permeability, which probably contributes to the increased
susceptibility to serum. Furthermore, loss of the outer membrane
protein OmpK36 contributes to enhanced antibiotic resistance and
is regularly observed in antibiotic resistant isolates (Xuan et al.,
2009). Deletion of the gene encoding the outer membrane pro-
tein OmpK36 increases serum resistance slightly (Chen et al., 2010),
but, in contrast, also increases the uptake by neutrophils and the
mutant is therefore less virulent in an animal model. The loss of a
direct interaction between OmpK36 and C1q may  explain enhanced
serum resistance in the ompK36 deletion mutant, although the
increase in phagocytosis indicates that complement is still func-
tional in the absence of OmpK36. These observations suggest that
antibiotic resistance and resistance to complement are delicately
balanced and may  make it difﬁcult to predict to what extent these
mechanisms contribute to the success of K. pneumoniae as a noso-
comial pathogen.
4.4. Other complement resistance strategies
As indicated above, complement evasion by K. pneumoniae
is mainly established by modifying the capsule, LPS or outer
membrane proteins. This strategy seemingly contrasts with the
mechanisms used by Gram-positive bacteria, which produce sev-
eral secreted proteins that directly inhibit or degrade complement
proteins (Laarman et al., 2010). Furthermore, several pathogens
express surface-associated molecules to attract host regulators of
complement. For instance, many bacteria express surface proteins
that recruit human factor H to their surface to inactivate surface-
bound C3b (Ferreira et al., 2010). For K. pneumoniae recruitment
of factor H or direct interaction with factor H has not yet been
described, but it has been suggested that sialic acid residues in the
K. pneumoniae capsule may  have this function or, alternatively, that
certain lipid A modiﬁcations may  have this role (Lee et al., 2014;
Lewis et al., 2010).
Screening methods using transposon mutagenesis have iden-
tiﬁed genes which are important for survival in serum or during
infection (Bachman et al., 2015). By analyzing a transposon mutant
library in a murine lung infection model several genes that are
important for survival of K. pneumoniae have been identiﬁed.
Among these genes was rfaH, a gene encoding a transcriptional
elongation factor. A rfaH deletion mutant showed increased serum
susceptibility and reduced ﬁtness in a murine lung infection model.
RfaH promotes the transcription of several virulence genes includ-
ing capsule and LPS synthesis genes, conﬁrming other studies
that showed that these structures are important for complement
resistance. Homologs of RfaH can be found in other pathogenic
Enterobacteriacecae, where they also contribute to virulence (Kong
et al., 2011; Nagy et al., 2002). Another K. pneumoniae gene, aroE,
which is involved in the synthesis of aromatic amino acids also
showed an increased susceptibility to serum, combined with a
decrease in mucoviscosity. The mechanism of serum resistance of
this mutant remains unclear.
Another  transposon mutant library screen to identify mutants
that are serum susceptible identiﬁed the htrA gene as being impor-
tant for serum survival (Cortés et al., 2002b). The htrA gene encodes
a serine protease that affects capsule formation. A htrA deletion
mutant showed increased opsonization with C3b and suscepti-
bility to serum killing. Notably, no K. pneumoniae proteins that
directly interact and evade killing by the complement system
were identiﬁed in transposon screens. Transposon mutant library
screenings with strains from different genetic backgrounds may
help to identify novel complement evasion proteins, especially
since K. pneumoniae has a large accessory genome with over 30,000
protein coding genes (Holt et al., 2015).
5. Directions for future research
Most studies on the interactions of K. pneumoniae with serum
primarily determine the extent by which strains are sensitive to
serum, but they do not determine whether the bactericidal effect of
serum is mediated by the complement system. Other antimicrobial
agents in serum, including phospholipases, lysozyme and ami-
dases, may  contribute to bacterial killing (Ellison and Giehl, 1991;
Markart et al., 2004; Mollner and Braun, 1984). Normally, heat
inactivation of serum is used to inactivate heat-labile complement
components, but this method can also inactivate other proteins
with an antimicrobial function. This was  recently illustrated in a
study which found that heat-inactivation blocked serum killing of
E. coli, but the bactericidal activity of serum was  not entirely abol-
ished upon addition of a speciﬁc complement inhibitor, indicating
that heat inactivation can destroy other bactericidal components in
serum (Berends et al., 2015). An approach to block the complement
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system by speciﬁc inhibitors or using sera in which speciﬁc com-
plement factors are depleted is essential to conﬁrm whether killing
is complement-dependent. Most studies in K. pneumoniae regard-
ing serum resistance focus on changes in the bacterial cell wall,
and, more speciﬁcally, on modiﬁcations of LPS or the capsule. These
modiﬁcations prevent proper deposition of complement proteins
in such a way that no or non-functional MAC  is formed (Merino
et al., 1992). From a bacterial point of view, inhibition of comple-
ment activation at the beginning of the cascade is beneﬁcial, since
next to MAC  formation, other effector functions such as phagocyto-
sis and neutrophil recruitment are then also blocked (Rooijakkers
et al., 2005).
Multi-drug resistance of K. pneumoniae limits current treatment
options to eradicate infections caused by this bacterium. There
is an urgent need for novel therapeutic strategies to prevent the
increase of life-threatening nosocomial and community-acquired
K. pneumoniae infections. Several antibiotics are ineffective in
Gram-negative bacteria due to their outer membrane barrier.
Agents that permeabilize the outer membrane barrier, although
lacking antibacterial activity themselves, may  sensitize K. pneu-
moniae and other Gram-negative bacteria to antibiotics that are
normally ineffective (Vaara et al., 2010). Interestingly, a combina-
tion of a polymyxin B derivative (PMBN) and serum has similar
synergistic effects (Vaara and Vaara, 1983). Heat-inactivation of
serum abolishes the synergy suggesting that PMBN enhances bacte-
ricidal activity of the MAC  or vice versa. The synergy between PMBN
and complement is incompletely understood, but probably desta-
bilization of the outer membrane sensitizes complement resistant
bacteria to the MAC. For instance, access and deposition of com-
plement components closer to the OM may  enhance the proper
integration of the MAC  into the bacterial OM.
6. Conclusions
K.  pneumoniae is ubiquitously present in the environment and
has a broad host range. Currently, hypervirulent strains that infect
healthy people are emerging, but most of the infections with K.
pneumoniae are still hospital-acquired and are difﬁcult to treat due
to the acquired antibiotic resistance. K. pneumoniae has developed
mechanisms to adapt during infection to ensure survival within
the host, which essentially comprise of improving existing bar-
riers that allow the bacterium to evade complement-dependent
killing.  The capsule and LPS play an essential role in these comple-
ment evasion methods, but are also important in protection against
other host defense mechanisms such as antimicrobial peptides. This
interplay between complement susceptibility and other bacterici-
dal components provides promising targets for the development
of novel therapies against K. pneumoniae. Moreover, compared
to other opportunistic pathogens K. pneumoniae does not secrete
host speciﬁc complement inhibitors. Therefore, its relatively lim-
ited complement resistance mechanisms may  also pave the way
for more directed immunotherapies to enhance complement-
dependent killing of these bacteria.
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